Form 4 Filing for Cellectar Biosciences, Inc.

This filing details a Form 4 submission for Cellectar Biosciences, Inc. (CLRB) concerning stock options granted to Andrew Gu, who is a director. The transaction, dated July 7, 2026, involves the acquisition of 25,000 stock options with an exercise price of $2.70 per share. These options are for the company's common stock and are set to expire on July 7, 2036. The options will vest in full on July 7, 2027, contingent upon Mr. Gu's continued service through the vesting date. Following this transaction, Mr. Gu holds 25,000 shares directly. The filing was signed on July 8, 2026, by Chad Kolean, acting as attorney-in-fact for Andrew Gu.